• Pharvaris NV PHVS.OQ reported a quarterly adjusted loss of 83 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -55 cents. The mean expectation of nine analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from -83 cents to -71 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Pharvaris NV's reported EPS for the quarter was a loss of 83 cents​.

• The company reported a quarterly loss of €45.48 million.

• Pharvaris NV shares had risen by 18.4% this quarter and gained 8.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Pharvaris NV is $30.00, about 30.5% above its last closing price of $20.84

This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)